News | Marking a new era in advancing genomic research at McGill
![](https://www.mcgill.ca/macdonald/files/macdonald/styles/fullwidth_breakpoints_theme_moriarty_small_1x/public/channels/image/victor-phillip-dahdaleh-genomic-medicine-810x500-art.jpg?itok=DdgjPLId×tamp=1724079753)
The McGill community, including researchers in genomic medicine and the health sciences, came together in July 2024 to mark the next phase of one of the University’s most rapidly growing disciplines and celebrate the generosity that is making it possible.
The occasion was the official unveiling of signage for the Victor Phillip Dahdaleh Institute of Genomic Medicine, and on hand were the Institute’s UK-based benefactors, Victor and Mona Dahdaleh, who were recognized for the far-reaching power of their philanthropy.
President Deep Saini marked the occasion by gratefully acknowledging the impact of the Dahdaleh’s landmark 2022 donation that created the Institute. “Your visionary philanthropy has cemented McGill’s reputation as a global hub for discovery and innovation in genomic medicine, and will serve as a catalyst for future advancements in this important field,” he said.
The philanthropic investment has already paid impressive dividends. It was an important factor in McGill’s successful application for a landmark $165-million grant from the Canada First Research Excellence Fund – the largest research grant in the University’s history – to launch a hub for genomics-based RNA therapeutics: McGill’s DNA to RNA initiative, dubbed D2R.
To read the full article by University Advancement, click here.